Erasca Reports Third Quarter 2026 Business Updates and Financial Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Erasca (Nasdaq: ERAS) reported third-quarter results and advanced ERAS-0015 after receiving FDA Fast Track designation for metastatic pancreatic adenocarcinoma. The designation was granted in August 2026. A July public offering raised approximately $632.5 million in gross proceeds. Cash, cash equivalents and marketable securities totaled $947.8 million at September 30, versus $341.8 million at year-end 2025.
Quarterly net loss widened to $51.3 million, or $0.15 per share, from $30.6 million, or $0.11 per share. Erasca expects preliminary ERAS-4001 data in H2 2026 and ERAS-0015 expansion and combination data in H1 2027. Three potentially registration-enabling ERAS-0015 trials are expected to start between H1 2027 and H1 2028 in pancreatic and lung cancers. The company expects current cash and securities to fund its listed upcoming milestones.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointCompleted July 2026 public offering raised approximately $632.5 million in gross proceeds. 11% of market cap
- Moderate pointCash and securities increased to $947.8 million at September 30, 2026, from $341.8 million at year-end 2025.
- Moderate pointERAS-0015 received FDA Fast Track designation for metastatic pancreatic adenocarcinoma in August 2026.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Erasca expects current cash and securities to fund its listed upcoming milestones.
- Moderate point. Forward-looking: it has not happened yet and may not happen.ERAS-0015 potentially registration-enabling trial in second-line-or-later non-small cell lung cancer is expected to begin in H1 2027.
- Moderate point. Forward-looking: it has not happened yet and may not happen.ERAS-0015 Phase 3 pivotal trial in first-line pancreatic ductal adenocarcinoma is expected to begin in 2027.
- Moderate point. Forward-looking: it has not happened yet and may not happen.ERAS-0015 Phase 3 pivotal trial in RAS-mutant non-small cell lung cancer is expected to begin in H2 2027–H1 2028.
9 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.ERAS-0015 Phase 1 monotherapy expansion data are expected in H1 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.ERAS-0015 Phase 1 combination dose-escalation data, including panitumumab, are expected in H1 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.ERAS-4001 preliminary Phase 1 safety, tolerability, pharmacokinetic and initial efficacy data are expected in H2 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.ERAS-4001 monotherapy expansion and combination dose-escalation cohorts are planned to begin in 2027.
- Minor pointWorking capital increased to $611.200 million at September 30, 2026, from $257.728 million at year-end 2025.
- Minor pointStockholders’ equity increased to $916.738 million at September 30, 2026, from $325.171 million at year-end 2025.
- Minor pointInterest income increased to $8.264 million in Q3 2026 from $3.971 million in Q3 2025.
- Minor pointNine-month interest income increased to $16.316 million in 2026 from $13.041 million in 2025.
- Minor pointQ3 in-process research and development expense fell to zero in 2026 from $2 million in 2025.
Negative
- Moderate pointQ3 net loss widened to $51.3 million, or $0.15 per share, from $30.6 million, or $0.11.
- Minor pointQ3 research and development expenses rose to $47.2 million in 2026 from $22.5 million in 2025.
- Minor pointQ3 general and administrative expenses rose to $12.3 million in 2026 from $10.1 million in 2025.
- Minor pointNine-month net loss widened to $278.850 million, or $0.87 per share, from $95.454 million, or $0.34.
- Minor pointNine-month in-process research and development expense rose to $150 million in 2026 from $9.5 million in 2025.
4 minor points
- Minor pointNine-month research and development expenses rose to $110.360 million in 2026 from $69.613 million in 2025.
- Minor pointNine-month general and administrative expenses rose to $34.691 million in 2026 from $29.188 million in 2025.
- Minor pointQ3 unrealized marketable-securities loss was $2.936 million, versus a $234,000 gain a year earlier.
- Minor pointNine-month unrealized marketable-securities loss was $4.813 million, versus a $244,000 gain a year earlier.
News Explained
In its reported Q3 results, Erasca gives weighted-average common shares used for EPS as 344,241,816, versus 283,681,570 a year earlier; the higher average share denominator does not establish the ownership effect of the
Key Figures
- Cash and marketable securities
- $947.8 million
- As of September 30, 2026
- R&D expenses
- $47.2 million vs. $22.5 million
- Quarter ended September 30, 2026 vs. 2025
- Net loss
- $51.3 million vs. $30.6 million
- Quarter ended September 30, 2026 vs. 2025
- Net loss per share
- $(0.15) vs. $(0.11)
- Basic and diluted; quarter ended September 30, 2026 vs. 2025
- Public offering gross proceeds
- Approximately $632.5 million
- Completed in July 2026
- Potentially registration-enabling trials
- Three
- ERAS-0015 trials in pancreatic and lung cancers
- ERAS-4001 preliminary data
- Expected in H2 2026
- Phase 1 monotherapy data
- ERAS-0015 data
- Expected in H1 2027
- Phase 1 monotherapy expansion and combination dose escalation
Previous Earnings Reports
-
Q2 report cited ERAS-0015 response data and July financing, relevant to program and cash updates.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
fast track designation regulatory
pharmacokinetics medical
gross proceeds financial
working capital financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers
Updated ERAS-0015 monotherapy and nonclinical ERAS-0015/ERAS-4001 combination data to be presented at ENA; expect preliminary ERAS-4001 data in H2 2026 and ERAS-0015 data in H1 2027
Cash, cash equivalents, and marketable securities of
SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended September 30, 2026.
“The emerging clinical profile of ERAS-0015 continues to support its potential as a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “We are rapidly advancing toward three potentially registration-enabling trials in pancreatic and lung cancers. We are pleased that ERAS-0015 received Fast Track Designation for metastatic pancreatic cancer, which offers an opportunity for closer engagement with the FDA as we progress the program. With a strengthened balance sheet and experienced R&D leadership, we believe that we are positioned to execute our near-term milestones and advance programs addressing high unmet needs for patients with RAS-mutant cancers.”
Research and Development (R&D) Highlights
- FDA Fast Track Designation for ERAS-0015: In August 2026, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma. The designation is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical needs and provides opportunities for more frequent FDA interactions as Erasca advances its planned Phase 3 trial in pancreatic cancer.
- Presentations at the 38th EORTC-NCI-AACR (ENA) Symposium: In September 2026, Erasca announced two presentations at the ENA Symposium, taking place November 18–20, 2026, in Barcelona, Spain. An oral plenary presentation will feature updated ERAS-0015 monotherapy data from the ongoing AURORAS-1 Phase 1 trial, including additional patients and longer follow-up. A poster presentation will feature nonclinical data for the combination of ERAS-0015 and ERAS-4001 targeting active and inactive KRAS, including synergy in KRAS G12X-driven models.
Corporate Highlights
- Strengthened R&D Leadership: In August 2026, Erasca appointed Charles Fuchs, M.D., M.P.H., as president of research and development, and David Chonzi, M.D., as senior vice president of global pharmacovigilance, both of whom joined Erasca’s leadership team.
- Completed Upsized Financing: In July 2026, Erasca completed a successful upsized public offering, raising approximately
$632.5 million in gross proceeds.
Key Upcoming Milestones
AURORAS-1 to -3: Trials for ERAS-0015 (potential best-in-class pan-RAS molecular glue)
- Phase 1 monotherapy expansion data expected in the first half of 2027
- Phase 1 combination dose escalation data, including panitumumab combination, expected in the first half of 2027
- Potentially registration-enabling trial in second line or greater NSCLC expected to initiate in the first half of 2027
- Phase 3 pivotal trial in first line PDAC expected to initiate in 2027
- Phase 3 pivotal trial in RASm NSCLC expected to initiate in the second half of 2027 to the first half of 2028
BOREALIS-1: Phase 1 trial for ERAS-4001 (potential first-in-class pan-KRAS inhibitor)
- Preliminary safety, tolerability, pharmacokinetics, and initial efficacy Phase 1 monotherapy data expected in the second half of 2026
- Initiation of monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027
Third Quarter 2026 Financial Results
Cash Position: Cash, cash equivalents, and marketable securities were
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative (G&A) Expenses: G&A expenses were
Net Loss: Net loss was
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Cautionary Note Regarding Forward-Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits for each of our product candidates, including ERAS-0015 and ERAS-4001; the potential for ERAS-0015 to be a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens; our belief that we are positioned to execute on our near-term milestones and advance programs addressing high unmet needs for patients with RAS-mutant cancers; the planned advancement of our development pipeline, including the anticipated timing of data readouts for the AURORAS-1 and BOREALIS-1 trials; our expectations related to the timing of the initiation of our clinical trials and patient cohorts; our belief that we are quickly advancing toward three potentially registration-enabling trials in pancreatic and lung cancers; our expectations that our planned clinical trials will serve as registration-enabling studies; the potential for ERAS-0015 to be best-in-class; the potential for ERAS-4001 to be first-in-class or best-in-class; and the sufficiency of our cash, cash equivalents, and marketable securities to fund the Key Upcoming Milestones set forth in this press release. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: the timing of our clinical data readouts, including for the AURORAS-1 to -3 and BOREALIS-1 trials, may be delayed; our product candidates, including ERAS-0015 and ERAS-4001, may not demonstrate therapeutic benefits that we expect; interim, topline and preliminary results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that an unconfirmed partial response to treatment may not ultimately result in a confirmed partial response to treatment after follow-up evaluations; FTD may not result in a more expedited development or regulatory review process, and such a designation does not increase the likelihood that ERAS-0015 will receive marketing approval in the United States; our approach to the discovery and development of product candidates is based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; results from preclinical studies not necessarily being predictive of future results; our assumptions around which programs may have a higher probability of success may not be accurate, and we may expend our limited resources to pursue a particular product candidate and/or indication and fail to capitalize on product candidates or indications with greater development or commercial potential; potential delays in the commencement, enrollment, data readout, and completion of clinical trials and preclinical studies; our dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; our planned potentially registration-enabling trials may be delayed based on FDA feedback or requirements, as the FDA retains broad discretion to require additional clinical data prior to the conduct of a registrational trial or submission for regulatory approval; even if our planned trials are successful, they may not support regulatory approval; unfavorable results from preclinical studies or clinical trials; the inability to realize any benefits from our current licenses, acquisitions, and collaborations, and any future licenses, acquisitions, or collaborations, and our ability to fulfill our obligations under such arrangements; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates and maintain our rights under intellectual property licenses, including our ability to successfully defend against allegations raised by, or any future litigation initiated by, Revolution Medicines (RevMed) that ERAS-0015 infringes patents held by RevMed or was derived from RevMed trade secrets; the sufficiency of our cash, cash equivalents, and marketable securities; we may use our capital resources sooner than we expect; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
| Erasca, Inc. Selected Condensed Consolidated Balance Sheet Data (In thousands) (Unaudited) | ||||||||
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Balance Sheet Data: | ||||||||
| Cash, cash equivalents, and marketable securities | $ | 947,820 | $ | 341,796 | ||||
| Working capital | 611,200 | 257,728 | ||||||
| Total assets | 998,936 | 396,154 | ||||||
| Accumulated deficit | (1,171,059 | ) | (892,209 | ) | ||||
| Total stockholders’ equity | 916,738 | 325,171 | ||||||
| Erasca, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 47,195 | $ | 22,474 | $ | 110,360 | $ | 69,613 | ||||||||
| In-process research and development | — | 2,000 | 150,000 | 9,500 | ||||||||||||
| General and administrative | 12,326 | 10,072 | 34,691 | 29,188 | ||||||||||||
| Total operating expenses | 59,521 | 34,546 | 295,051 | 108,301 | ||||||||||||
| Loss from operations | (59,521 | ) | (34,546 | ) | (295,051 | ) | (108,301 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest income | 8,264 | 3,971 | 16,316 | 13,041 | ||||||||||||
| Other expense, net | (74 | ) | (37 | ) | (115 | ) | (194 | ) | ||||||||
| Total other income (expense), net | 8,190 | 3,934 | 16,201 | 12,847 | ||||||||||||
| Net loss | $ | (51,331 | ) | $ | (30,612 | ) | $ | (278,850 | ) | $ | (95,454 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.15 | ) | $ | (0.11 | ) | $ | (0.87 | ) | $ | (0.34 | ) | ||||
| Weighted-average shares of common stock used in computing net loss per share, basic and diluted | 344,241,816 | 283,681,570 | 320,111,548 | 283,434,073 | ||||||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Unrealized (loss) gain on marketable securities, net | (2,936 | ) | 234 | (4,813 | ) | 244 | ||||||||||
| Comprehensive loss | $ | (54,267 | ) | $ | (30,378 | ) | $ | (283,663 | ) | $ | (95,210 | ) | ||||
Investor Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
Source: Erasca, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much cash did Erasca have at September 30, 2026?
Erasca held $947.8 million in cash, cash equivalents and marketable securities at September 30, 2026, compared with $341.8 million at December 31, 2025. The company expects those resources to fund its listed upcoming milestones.
When does Erasca expect its next ERAS-0015 and ERAS-4001 clinical data?
Erasca expects preliminary ERAS-4001 Phase 1 data in H2 2026 and ERAS-0015 monotherapy expansion and combination dose-escalation data in H1 2027. The ERAS-4001 readout is expected to cover safety, tolerability, pharmacokinetics and initial efficacy.
What will Erasca present at the November 2026 ENA Symposium?
Erasca will present updated ERAS-0015 monotherapy clinical data and nonclinical ERAS-0015/ERAS-4001 combination data at the November 18–20, 2026, symposium in Barcelona. The oral presentation includes additional AURORAS-1 Phase 1 patients and longer follow-up; the poster includes combination synergy in KRAS G12X-driven models.
Who joined Erasca’s research and development leadership in August 2026?
Charles Fuchs joined as president of research and development, and David Chonzi joined as senior vice president of global pharmacovigilance in August 2026. Both joined Erasca’s leadership team.